EUVIMEDEUVIMED entdecken
Editorial

What can epigenomics tell us about prostate cancer disparities?

Carmen Ortiz-Sánchez, Jong Y Park

Epigenomics · 03.10.2026 · 18 (10) · 1189-1192

DOI: 10.1080/17501911.2026.2745488 ↗

Kurz gefasst

Editorial in der Zeitschrift Epigenomics, online erschienen am 11.10.2026. Verfasst von Carmen Ortiz-Sánchez und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Sciences, Ponce Research Institute, Ponce Health Sciences University, Ponce, Puerto Rico. Die Arbeit nennt 19 Literaturangaben. Gefördert von: NCI NIH HHS, U54 PHSU-MCC Partnership.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

1. Prostate cancer is the second most commonly diagnosed cancer among men worldwide, with approximately 1.47 million new cases reported in 2022 [1]. However, this burden is not distributed equally ...

Schlagwörter

Stichwörter der Autor:innen

DNA methylationEpigenomicsHispanic populationhealth disparitiesprostate cancer

Autor:innen und Institutionen

  • Department of Basic Sciences, Ponce Research Institute, Ponce Health Sciences University, Ponce, Puerto Rico.
  • Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.

Förderung

  • NCI NIH HHS
  • U54 PHSU-MCC Partnership

Zitieren

APA

Ortiz-Sánchez, C., & Park, J. Y. (2026). What can epigenomics tell us about prostate cancer disparities?. Epigenomics, 18(10), 1189-1192. https://doi.org/10.1080/17501911.2026.2745488

Vancouver

Ortiz-Sánchez C, Park JY. What can epigenomics tell us about prostate cancer disparities?. Epigenomics. 2026;18(10):1189-1192. doi:10.1080/17501911.2026.2745488

BibTeX
@article{OrtizSnchez2026,
  author = {Ortiz-Sánchez, Carmen and Park, Jong Y},
  title = {What can epigenomics tell us about prostate cancer disparities?},
  journal = {Epigenomics},
  year = {2026},
  volume = {18},
  number = {10},
  pages = {1189--1192},
  doi = {10.1080/17501911.2026.2745488}
}
Kostenlos starten →